Skip to Main Content

Paper Details

A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11).
Clin Cancer Res
10
2022
Gemcitabine, NPC, Nivolumab, PD, PD-1, PD-L1, Patients, advanced NPC, anemia, chromatin modifier gene, gemcitabine, hypertension, immune-excluded immune phenotype, nasopharyngeal carcinoma, nivolumab, patients, platinum, programmed death 1, programmed death ligand 1, tumor, tumor-infiltrating lymphocyte, tumors
Author NameAffiliation
Woong-Yang ParkSamsung Advanced Institute for Health Science and Technology, Sungkyunkwan University
Woong-Yang ParkSamsung Genome Institute, Samsung Medical Center, Sungkyunkwan University
Woong-Yang ParkSamsung Advanced Institute for Health Science and Technology, Sungkyunkwan University
Woong-Yang ParkSamsung Genome Institute, Samsung Medical Center, Sungkyunkwan University
Bhumsuk KeamSeoul National University Hospital
  • 1 - 5

Datasets

Release 1.2